Therefore, normalizing the synaptic balance by inhibiting the common synaptolytic factor FAM19A5 with NS101 offers a promising therapeutic approach for various neurological diseases characterized by excessive synapse loss arising from either external synaptolytic factors and/or increased FAM19A5 levels. Here, TAFA5 is linked to nervous system disorder.